Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...
Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...
Accurately diagnosing T-cell lymphoma often takes time. Given that cutaneous T-cell lymphoma shares symptoms with many other benign conditions, it takes an average of 6 years from disease onset to ...
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...
BI-1808 as monotherapy in Cutaneous T Cell Lymphoma (CTCL) will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California. The data, previously disclosed ...
LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...
The event was aimed at helping more patients find a stem cell match, including Philip, the father of Exeter MA Law student ...
On January 14, 2025, the Company reported positive outcomes observed from the interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryteTM treatment for up to 12 ...
Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback